Faricimab appears noninferior to aflibercept for improving BCVA in wet AMD
- Posted on: Feb 23 2022
- Leave a response
Faricimab was approved by the FDA in January 2022 for the treatment of neovascular AMD and diabetic macular edema (DME). This approval was partially based on 2 phase 3 studies, which also showed the potential to extend the time between treatments.
Source: AAO
Posted in: Uncategorized
